Regulation of the IgE Antibody Response

Progress in Allergy

Vol. 32

Series Editors

Kimishige Ishizaka, Baltimore, Md.; Paul Kallös, Heisingborg;
Byron H. Waksman, New York, N.Y., and A lain L. de Weck, Bern

S. Karger • Basel • München • Paris • London • New York • Sydney

Regulation of the
IgE Antibody Response

Volume Editor
Kimishige Ishizaka, Baltimore, Md.

Contributors
H. Bazin, Brussels; K. Blaser, Bern; B.E. Bozelka, New Orleans, La.;
K. Ishizaka, Baltimore, Md.; D.H. Katz, La Jolla, Calif.;
T. Kishimoto, Osaka; S.B. Lehrer, New Orleans, La.; P.S. Norman,
Baltimore, Md.; R. Pauwels, Ghent; A.H. Sehon, Winnipeg, Manit.;
A.L. de Weck, Bern

68 figures and 51 tables, 1982

S. Karger • Basel • München • Paris • London • New York • Sydney

Progress in Allergy

Vol. 30: Recent Trends in Allergen and Complement Research. P. Kallös, Helsingborg (ed.)
Vol. 31: Immunity and Concomitant Immunity in Infectious Diseases. P. Kallös, Helsingborg
(ed.)
ISBN 3-8055-3464-7

National Library of Medicine, Cataloging in Publication

Regulation of the IgE antibody response

Volume editor, Kimishige Ishizaka; contributors, H. Bazin [et al.], - Basel, New York, Karger 1982
Drug Dosage
The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved
No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

© Copyright 1982 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)
Printed in Switzerland by Buchdruckerei ‘Der Bund’ Bern
ISBN 3-8055-3470-1

Contents

Introduction
K. Ishizaka, Baltimore, Md 1
Mouse IgE
S.B. Lehrer; B.E. Bozelka, New Orleans, La 8
Introduction 9
Why Mouse IgE? 9
Historical Background 10
IgE Biosynthesis 11
Cellular Interactions 11
Site of Synthesis 12
Contents VII

IgE Antibody Responses in vitro: from Rodents to Man
D.H. Katz, La Jolla, Calif 105

Introduction 105

Variations in Systems Employed for in vitro IgE Synthesis 106
Synthesis of IgE by Cultured Rabbit Lymphoid Cells 107
In vitro Stimulation of Rat Lymphoid Cells To Become IgE-Producing Cells 108
In vitro Biosynthesis of IgE by Cultured Mouse Lymphoid Cells 110
In vitro Biosynthesis of IgE by Human Peripheral Blood Mononuclear Cells 114
Culture Systems in which PWM Failed To Stimulate IgE Synthesis 115
Culture Systems in which PWM Stimulated IgE Synthesis 118
Explanations for the Conflicting Findings on the Ability of PWM To Stimulate
Human IgE Synthesis in vitro 125
Stimulation of Human IgE Synthesis in vitro by Soluble Antigen or a
Mixture of Soluble Antigen plus PWM 126
Lymphocytes Expressing Specific Fc Receptors for IgE (FcRe) 130
Soluble Factors Regulating IgE Responses in vitro 136
Regulatory Factors with Binding Affinity for IgE 139
Serum-Derived Suppressive Factor of Allergy and Enhancing Factor of Allergy 144
Conclusions 151
Acknowledgments 152
References 152

Suppression of IgE Antibody Responses with Tolerogenic Conjugates of Allergens and Haptens
A.H. Sehon, Winnipeg, Manit 161

Introduction 161
Current Hyposensitization Methods for IgE-Mediated Allergies 162
Brief Overview of Cellular Interactions Regulating the Antibody Response with Reference to IgE Production 165
New Strategies for the Specific Downregulation of the IgE Response 168
Use of Immunosuppressive Conjugates of Isologous γ-Globulins or of Copolymers of D-Glutamic Acid and D-Lysine with Haptens and Proteins 169
Generation of Suppressor T Cells by Modified Allergens 170
Antigen-PEG Systems 171
Hapten-PVA Systems 180

Relationship between Suppression of Circulating IgE Antibodies and the State of Sensitivity of Animals Treated by Tolerogenic Conjugates 187
Suppression of Systemic Sensitivity of RAG-Sensitive Dogs Following Treatment with RAG-mPEG Conjugates 187
Suppression of Systemic Sensitivity of BPO-Sensitive Mice Following Treatment with BPO-PVA Conjugates 189

Contents VIII

Conclusions 193
Acknowledgements 194
References 194

Regulation of the IgE Antibody Response by Idiotype-Anti-Idiotype Network
K. Blaser; A.L. de Weck, Bern 203

Idiotype-Anti-Idiotype Regulation : Current State 204
Introduction 204
Regulation of the Immune Response by a Network of Idiotypes 206
Contents IX

IgE Class-Specific Suppressor T Cells and Regulation of the IgE Response
T. Kishimoto, Osaka 265

Introduction 265
Cells Involved in the IgE Antibody Response 266
Interaction of T and B Cells in the IgE Response 266
IgE Class-Specific Helper T Cells and Isotype-Specific Regulation of the Antibody Response 268
Induction and Characterization of IgE Class-Specific Suppressor T Cells 271
Induction of IgE Class-Specific Suppressor T Cells 271
Are IgE Class-Specific Suppressor T Cells Antigen-Specific or Non-Specific? 274
Suppression of the in vivo IgE Response by Suppressor T Cells 278
T Cell Factors Regulating the IgE Antibody Response 283
IgE Class-Specific Helper or Potentiating Factor(s) 283
IgE Class-Specific Suppressor Factor(s) 286
Target Cells of IgE Class-Specific Suppressor Factor(s) 291
IgE Class-Specific Suppressor T Hybridoma and Its Products 299
IgE-B Cells, the Target Cells of IgE Class-Specific Suppressor Factor 303
Conclusion and Future Prospects 307
Acknowledgment 310
References 310

Immunotherapy
P.S. Norman, Baltimore, Md 318

Introduction 318
‘Prophylactic Inoculations’ 319
Desensitization 320
Blocking Antibodies 320
Controlled Studies 321
Immunologic Correlates 323
IgE Antibodies 326
Specificity of Immunotherapy 327
Antibodies in Secretions 329
Clinically Useful Allergens for Immunotherapy 331
Problem Areas 333
Depot Methods 334
Cross-Linked or Polymerized Antigens 335
Lymphocyte Reactions 336
Suppression of IgE Antibodies 337
References 339